Current Research into Cures for Type-1 Diabetes

I'm embarrassed about this blog posting, because it is very late.  It reports on news announced about 18 months ago.  I was digging thr...

This is a combination of updates from the last month or two. DILfrequency Completes Data Collection In late may, the DILfrequency resear...

Every year the American Diabetes Association holds the largest diabetes conference of the year.  This year it was in New Orleans.  Attendanc...

ATG is Anti-Thymocyte Globulin, a biological agent used to lower immune reactions. GCSF is Granulocyte Colony-Stimulating Factor, a biolog...

This posting discusses two treatments which have the potential to cure type-1 diabetes, which have been tested on people, and which were rep...

At the 2014 ADA Scientific Sessions, there were several reports on progress on artificial pancreas (sometimes called "closed loop...

This blog posting is a collection of little news items, rather than a single large one. Two Year Delay for LCT In a very brief announcem...

Prologue: Why Completing Enrollment is an Important Milestone for Clinical Trials For two reasons.  First, because at that point it is p...

ATG + GCSF Starts a Phase-I Clinical Trial This is a very interesting study, which is why I'm giving it, it's own blog posting.  ...

Dr. Gitelman at UCSF has started a Phase-II human trial aimed at using ATG to cure (or lessen) type-1 diabetes. The goal of this study is ...